Search results for "fluticasone"

showing 6 items of 56 documents

Mepolizumab for eosinophilic chronic obstructive pulmonary disease

2017

BACKGROUNDPatients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.METHODSWe performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizumab (100 mg in METREX, 100 or 300 mg in METREO) with placebo, given as a subcutaneous injection every 4 weeks for 52 weeks in patients with COPD who had a history of moderate or severe exacerbations while taking inhaled glucocorticoid-based triple maintenance therapy. In METREX, unselected patients in the modified intention-to-treat population with an eosinophilic phenotype were …

medicine.medical_specialtyPARALLEL-GROUPPopulationPlacebo-controlled studyPNEUMONIA RISKPlaceboPLACEBO-CONTROLLED TRIALGastroenterology03 medical and health sciencesDOUBLE-BLIND0302 clinical medicineMaintenance therapyInternal medicineEosinophilicmedicineINHALED FLUTICASONE FUROATE030212 general & internal medicineeducationCOPDeducation.field_of_studyIntention-to-treat analysisCOPD ASSESSMENT TESTSPUTUM EOSINOPHILIAbusiness.industryGeneral MedicineRANDOMIZED CONTROLLED-TRIALBLOOD EOSINOPHILSmedicine.diseaseSECONDARY ANALYSIS030228 respiratory systemImmunologybusinessMepolizumabmedicine.drug
researchProduct

Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma

2004

Background In asthma T cells are characterized by an increased activation state and by reduced apoptosis. Objective Because the clinical efficacy of inhaled corticosteroids combined with long-acting β 2 -agonists has been widely demonstrated in asthma, we studied, in vitro , the effect of fluticasone propionate (FP) and salmeterol alone and in combination on the activation and apoptosis of peripheral blood T cells (PBTs), on the expression of phosphorylated nuclear factor κB inhibitor (IκBα), and on the nuclear translocation of glucocorticoid receptor (GR) in PBTs from asthmatic subjects. Methods Apoptosis was evaluated on the basis of annexin V binding, whereas the expression of caspases 8…

medicine.medical_specialtyProgrammed cell deathAdolescentT cellT-LymphocytesImmunologyActive Transport Cell NucleusApoptosisAndrostadienes; Active Transport Cell Nucleus; NF-kappa B; Apoptosis; Humans; Albuterol; Receptors Glucocorticoid; Asthma; Child; Caspases; Lymphocyte Activation; Phosphorylation; I-kappa B Proteins; Adolescent; Drug Synergism; T-LymphocytesLymphocyte ActivationGlucocorticoid receptorReceptors GlucocorticoidNF-KappaB Inhibitor alphaAnnexinInternal medicinemedicineHumansImmunology and AllergyAlbuterolPhosphorylationChildSalmeterol XinafoateAndrostadieneChemistryActive Transport Cell NucleuNF-kappa BApoptosiDrug SynergismCaspaseAsthmaAndrostadienesIκBαEndocrinologymedicine.anatomical_structureApoptosisCaspasesFluticasoneI-kappa B ProteinI-kappa B ProteinsSalmeterolGlucocorticoidmedicine.drugHuman
researchProduct

Cigarette smoke alters non-neuronal cholinergic system components inducing MUC5AC production in the H292 cell line.

2013

Abstract Cigarette smoke extract (CSE) affects the expression of Choline Acetyl-Transferase (ChAT), muscarinic acetylcholine receptors, and mucin production in bronchial epithelial cells. Mucin 5AC (MUC5AC), muscarinic acetylcholine receptor M3, ChAT expression, acetylcholine levels and acetylcholine binding were measured in a human pulmonary mucoepidermoid carcinoma cell line (H292) stimulated with CSE. We performed ChAT/RNA interference experiments in H292 cells stimulated with CSE to study the role of ChAT/acetylcholine in MUC5AC production. The effects of Hemicholinium-3 (HCh-3) (50 μM) (a potent and selective choline uptake blocker) and Tiotropium bromide (Spiriva ® ) (100 nM), alone o…

medicine.medical_specialtyScopolamine DerivativesBronchiComplex MixturesMucin 5ACCholinergic AntagonistsCholine O-Acetyltransferasechemistry.chemical_compoundAcetylcholine bindingInternal medicineCell Line TumorSmokeparasitic diseasesMuscarinic acetylcholine receptorTobaccomedicineCholineHumansSecretionAlbuterolNeurotransmitter Uptake InhibitorsTiotropium BromideAutocrine signallingSalmeterol XinafoatePharmacologyReceptor Muscarinic M3Epithelial CellsHemicholinium 3respiratory systemCholine acetyltransferaseAcetylcholineBronchodilator AgentsAndrostadienesEndocrinologychemistryCell cultureFluticasoneRNA InterferenceAcetylcholinemedicine.drugEuropean journal of pharmacology
researchProduct

1539 Length of Hospital Stay in Children with Acute Viral Pneumonia Treated with Corticosteroids, A Retrospective Study

2012

Background Corticosteroids with or without ephedrine may have positive effects in viral pneumonia treatment accelerating the time to resolution of symtpoms but the evidence is not strong enough to make specific recommandations. Objectives Evaluating the hospital length stay of the children with viral pneumonia treated with corticosteroids, single or in combination with ephedrine. Material and Methods The retrospective study included pacients admitted in our clinic with viral pneumonia during 2011. From 167 cases, 78 cases were selected according to specific criteria: patients having received cortisone (hydrocortisone hemisuccinate and/or fluticasone propionate) associated or not with ephedr…

medicine.medical_specialtybiologybusiness.industryC-reactive proteinRetrospective cohort studymedicine.diseaseFluticasone propionateSurgeryAerosol therapyInternal medicineViral pneumoniaPediatrics Perinatology and Child Healthmedicinebiology.proteinCortisoneEphedrinebusinessHospital staymedicine.drugArchives of Disease in Childhood
researchProduct

Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simula…

2020

Omar S Usmani,1 Nicola Scichilone,2 Benjamin Mignot,3 Dennis Belmans,3 Cedric Van Holsbeke,3 Jan De Backer,3 Roberta De Maria,4 Erika Cuoghi,4 Eva Topole,4 George Georges4 1Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK; 2PROMISE Department of Medicine, University of Palermo, Palermo, Italy; 3FLUIDDA, Kontich, Belgium; 4Chiesi Farmaceutici, SpA, Parma, ItalyCorrespondence: George GeorgesChiesi USA Inc., 175 Regency Woods Place, Ste. 600, Cary, NC 27518, USATel +1 (919) 678 6611 x1536Email george.georges@chiesi.comIntroduction: There is a clear correlation between small airways dysfunction and poor clinical outcomes in patients with chronic obstructiv…

medicine.medical_specialtymedicine.drug_classRespiratory SystemUrologyInternational Journal of Chronic Obstructive Pulmonary DiseaseSettore MED/10 - Malattie Dell'Apparato RespiratoriotomographyDry powder inhalers Inhaled corticosteroid Long-acting beta2 agonist Long-acting muscarinic antagonist Metered dose inhalers Tomography X-ray computedinhaled corticosteroidFluticasone propionatePulmonary Disease Chronic Obstructivechemistry.chemical_compoundFormoterol FumarateBronchodilatorAdministration InhalationmedicineHumanslong-acting muscarinic antagonistComputer SimulationGlycopyrronium bromideRespiratory systemmetered dose inhalers1102 Cardiorespiratory Medicine and HaematologyOriginal Researchx-ray computedlcsh:RC705-779COPDScience & TechnologyInhalationbusiness.industrydry powder inhalersGeneral Medicinelcsh:Diseases of the respiratory systemrespiratory systemmedicine.diseaseBronchodilator AgentsDrug CombinationschemistryCorticosteroidVilanterolbusinessLife Sciences & Biomedicinelong-acting beta2 agonistmedicine.drugInternational Journal of COPD
researchProduct

A double-blind, placebo-controlled comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal allergic rhinitis

1999

Fluticasone propionate aqueous nasal spray (FPANS) is a topically active glucocorticoid which has been successfully used for the treatment of seasonal allergic rhinitis (SAR). Topical levocabastine is a highly selective H1 antagonist which has been proposed as an alternative treatment of SAR. The purpose of this study was to compare the clinical efficacy of two topical nasal treatments, FPANS and levocabastine, in the treatment of SAR. Additionally, the effect of treatments on nasal inflammation was examined during natural pollen exposure. A group of 288 adolescent and adult patients with at least a 2-year history of SAR to seasonal pollens participated in a multicenter, doubleblind, double…

rhinorrheamedicine.drug_classbusiness.industrymedicine.medical_treatmentImmunologyPlaceboFluticasone propionateLevocabastineNasal sprayAnesthesiaotorhinolaryngologic diseasesmedicineImmunology and AllergyNasal Lavagemedicine.symptombusinessH1 antagonistmedicine.drugFluticasoneAllergy
researchProduct